Cargando…

Identification of Actionable Fusions as an Anti-EGFR Resistance Mechanism Using a Circulating Tumor DNA Assay

PURPOSE: Gene fusions are established oncogenic drivers and emerging therapeutic targets in advanced colorectal cancer. This study aimed to detail the frequencies and clinicopathological features of gene fusions in colorectal cancer using a circulating tumor DNA assay. METHODS: Circulating tumor DNA...

Descripción completa

Detalles Bibliográficos
Autores principales:	Clifton, Katherine, Rich, Thereasa A., Parseghian, Christine, Raymond, Victoria M., Dasari, Arvind, Pereira, Allan Andresson Lima, Willis, Jason, Loree, Jonathan M., Bauer, Todd M., Chae, Young Kwang, Sherrill, Gary, Fanta, Paul, Grothey, Axel, Hendifar, Andrew, Henry, David, Mahadevan, Daruka, Nezami, Mohammad Amin, Tan, Benjamin, Wainberg, Zev A., Lanman, Richard, Kopetz, Scott, Morris, Van
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society of Clinical Oncology 2019
Materias:	Original Reports
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7526699/ https://www.ncbi.nlm.nih.gov/pubmed/33015522 http://dx.doi.org/10.1200/PO.19.00141

Ejemplares similares

Mechanisms of resistance to EGFR-targeted therapies in colorectal cancer: more than just genetics
por: Parseghian, Christine, et al.
Publicado: (2023)

Recent developments in the treatment of metastatic colorectal cancer
por: Loree, Jonathan M., et al.
Publicado: (2017)

Antibiotic Exposure Does Not Impact Immune Checkpoint Blockade Response in MSI-H/dMMR Metastatic Colorectal Cancer: A Single-Center Experience
por: Serpas Higbie, Victoria, et al.
Publicado: (2022)

Emerging Role and Targeting of Carcinoembryonic Antigen-related Cell Adhesion Molecule 6 (CEACAM6) in Human Malignancies
por: Johnson, Benny, et al.
Publicado: (2015)

In Silico analyses of host immunity and stroma provide prognostic factors in early stage pancreatic ductal adenocarcinoma (PDAC)
por: Williams, Madison H., et al.
Publicado: (2020)

Revisiting Epidermal Growth Factor Receptor (EGFR) Amplification as a Target for Anti-EGFR Therapy: Analysis of Cell-Free Circulating Tumor DNA in Patients With Advanced Malignancies
por: Kato, Shumei, et al.
Publicado: (2019)

Overall Survival in Phase 3 Clinical Trials and the Surveillance, Epidemiology, and End Results Database in Patients With Metastatic Colorectal Cancer, 1986-2016: A Systematic Review
por: Shen, Chan, et al.
Publicado: (2022)

Targeting colorectal cancer with human anti-EGFR monoclonocal antibodies: focus on panitumumab
por: Kim, George P, et al.
Publicado: (2008)

Reducing Skin Toxicities from EGFR Inhibitors with Topical BRAF Inhibitor Therapy
por: Lacouture, Mario E., et al.
Publicado: (2021)

Clinical trials targeting neurofibromatoses-associated tumors: a systematic review
por: Roman Souza, Gabriel, et al.
Publicado: (2022)

Underreporting of race/ethnicity in COVID-19 research
por: Raghav, Kanwal, et al.
Publicado: (2021)

Targeted Therapies for Metastatic Esophagogastric Cancer
por: Reddy, Deepa, et al.
Publicado: (2011)

A Comparative Analysis of Tumors and Plasma Circulating Tumor DNA in 145 Advanced Cancer Patients Annotated by 3 Core Cellular Processes
por: Larson, Kristian, et al.
Publicado: (2020)

Survival improvement for patients with metastatic colorectal cancer over twenty years
por: Zeineddine, Fadl A., et al.
Publicado: (2023)

Representativeness of Black Patients in Cancer Clinical Trials Sponsored by the National Cancer Institute Compared With Pharmaceutical Companies
por: Unger, Joseph M, et al.
Publicado: (2020)

Reciprocal feedback inhibition of the androgen receptor and PI3K as a novel therapy for castrate-sensitive and -resistant prostate cancer
por: Qi, Wenqing, et al.
Publicado: (2015)

Expression Levels of RAD51 Inversely Correlate with Survival of Glioblastoma Patients
por: Morrison, Christopher, et al.
Publicado: (2021)

What is the role of histone H1 heterogeneity? A functional model emerges from a 50 year mystery
por: Parseghian, Missag Hagop
Publicado: (2015)

Individualized therapies in colorectal cancer: KRAS as a marker for response to EGFR-targeted therapy
por: Chang, David Z, et al.
Publicado: (2009)

The c-Met receptor tyrosine kinase inhibitor MP470 radiosensitizes glioblastoma cells
por: Welsh, James W, et al.
Publicado: (2009)

Using cfDNA and ctDNA as Oncologic Markers: A Path to Clinical Validation
por: Dao, Jonathan, et al.
Publicado: (2023)

Clinical correlates of blood-derived circulating tumor DNA in pancreatic cancer
por: Patel, Hitendra, et al.
Publicado: (2019)

Rare Tumor-Normal Matched Whole Exome Sequencing Identifies Novel Genomic Pathogenic Germline and Somatic Aberrations
por: Sprissler, Ryan, et al.
Publicado: (2020)

Role of PD-1 Inhibitors in the Treatment of Esophagogastric Adenocarcinoma: Patient Selection and Reported Outcomes
por: Epistola, Raisa, et al.
Publicado: (2023)

Phosphorylated EGFR Dimers Are Not Sufficient to Activate Ras
por: Liang, Samantha I., et al.
Publicado: (2018)

Bintrafusp Alfa, an Anti-PD-L1:TGFβ Trap Fusion Protein, in Patients with ctDNA-positive, Liver-limited Metastatic Colorectal Cancer
por: Morris, Van K., et al.
Publicado: (2022)

Clinical activity of the EGFR tyrosine kinase inhibitor osimertinib in EGFR-mutant glioblastoma
por: Makhlin, Igor, et al.
Publicado: (2019)

Phase II study of durvalumab (anti-PD-L1) and trametinib (MEKi) in microsatellite stable (MSS) metastatic colorectal cancer (mCRC)
por: Johnson, Benny, et al.
Publicado: (2022)

Co-targeting aurora kinase with PD-L1 and PI3K abrogates immune checkpoint mediated proliferation in peripheral T-cell lymphoma: a novel therapeutic strategy
por: Islam, Shariful, et al.
Publicado: (2017)

TP53 Mutations as a Driver of Metastasis Signaling in Advanced Cancer Patients
por: Pandey, Ritu, et al.
Publicado: (2021)

Meta-analyses of treatment standards for pancreatic cancer
por: GONG, JUN, et al.
Publicado: (2016)

DNA methylation biomarkers discovered in silico detect cancer in liquid biopsies from non-small cell lung cancer patients
por: Vrba, Lukas, et al.
Publicado: (2019)

Drug-induced aneuploidy and polyploidy is a mechanism of disease relapse in MYC/BCL2-addicted diffuse large B-cell lymphoma
por: Islam, Shariful, et al.
Publicado: (2018)

Retreatment with anti-EGFR based therapies in metastatic colorectal cancer: impact of intervening time interval and prior anti-EGFR response
por: Liu, X., et al.
Publicado: (2015)

Association of Prediagnosis Obesity and Postdiagnosis Aspirin With Survival From Stage IV Colorectal Cancer
por: Davis, Jennifer S., et al.
Publicado: (2022)

MP470, a novel receptor tyrosine kinase inhibitor, in combination with Erlotinib inhibits the HER family/PI3K/Akt pathway and tumor growth in prostate cancer
por: Qi, Wenqing, et al.
Publicado: (2009)

PD-1-Associated Gene Expression Signature of Neoadjuvant Trastuzumab-Treated Tumors Correlates with Patient Survival in HER2-Positive Breast Cancer
por: Hendricks, William P. D., et al.
Publicado: (2019)

Genomic Assessment of Blood-Derived Circulating Tumor DNA in Patients With Colorectal Cancers: Correlation With Tissue Sequencing, Therapeutic Response, and Survival
por: Kato, Shumei, et al.
Publicado: (2019)

Development of an artificial intelligence-derived histologic signature associated with adjuvant gemcitabine treatment outcomes in pancreatic cancer
por: Nimgaonkar, Vivek, et al.
Publicado: (2023)

Final results of DESTINY-CRC01 investigating trastuzumab deruxtecan in patients with HER2-expressing metastatic colorectal cancer
por: Yoshino, Takayuki, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_56hccu1lr47dapu0pmi0iqa8fi